Tchernev Georgi, Chokoeva Anastasiya Atanasova, Ivanova Bogdana, Mangarov Hristo, Vidolova Nadezhda Georgieva
Medical Institute of Minitry of Interior (MVR-Sofia), Chair of Department of Dermatology, Venereology and Dermatologic Surgery, General Skobelev Nr 79, 1606, Sofia, Bulgaria.
"Onkoderma"-Policlinic for Dermatology and Dermatologic Surgery, General Skobelev 26 blvd., Sofia, Bulgaria.
Wien Med Wochenschr. 2017 Mar;167(3-4):85-88. doi: 10.1007/s10354-016-0484-8. Epub 2016 Jul 28.
Porokeratosis is defined as a disorder of keratinization characterized by one or more atrophic patches surrounded by a clinically and histologically distinctive hyperkeratotic ridgelike border called the cornoid lamella. Lesions are most commonly located on the sun-exposed sides of trunk and extremities, while exclusive facial involvement has been also reported. Despite that the exact risk of cutaneous malignancy developing in porokeratosis is unknown, it is confirmed by series of case reports, including squamous cell carcinoma, basal cell carcinoma and even melanoma. Although no definite cure exists, a number of treatment modalities, from topical medications to laser and light devices, have been reported with variable success. Although promising, reports of disseminated superficial actinic porokeratosis treated with vitamin D3 analogs are rare. No satisfactory enough effect is obtained also with calcipotriol monotherapy.We report a case of disseminated superficial actinic porokeratosis in a 80-year-old female patient, successfully treated with combination of topical calcipotriol/betamethasone gel. A significant improvement was noticed after 3 weeks; almost full resolution of the clinical symptoms without appearance of fresh lesions was achieved in the second month. To the best of our knowledge, this is the first report of successful treatment with full resolution in a short interval, by simultaneous application of vitamin D3 analog (calcipotriol) and corticosteroid (betamethasone), combined in a one commercial product as a gel for treatment of keratinocyte proliferation's disorder such as psoriasis vulgaris. This promising new entity seems to be more effective, because of the simultaneous synergetic effects of the substations, namely the normalization of the proliferation of the keratinocytes by calcipotriol on one hand, and the reducing of the inflammation by the corticosteroid on another. Sun protection stays always mandatory, as well as the regular clinical observation, regarding the risk of malignant transformation.
汗孔角化症被定义为一种角化异常疾病,其特征为一个或多个萎缩性斑块,周围环绕着临床上和组织学上独特的角化过度嵴状边缘,称为鸡眼样板。病变最常位于躯干和四肢暴露于阳光的部位,也有仅累及面部的报道。尽管汗孔角化症发生皮肤恶性肿瘤的确切风险尚不清楚,但一系列病例报告已证实其可发生鳞状细胞癌、基底细胞癌甚至黑色素瘤。虽然尚无确切的治愈方法,但已报道了多种治疗方式,从局部用药到激光和光设备,效果各异。尽管维生素D3类似物治疗播散性浅表性光化性汗孔角化症前景看好,但相关报道很少。单用卡泊三醇治疗也未取得足够令人满意的效果。我们报告了一例80岁女性播散性浅表性光化性汗孔角化症患者,采用外用卡泊三醇/倍他米松凝胶联合治疗取得成功。3周后可见明显改善;第二个月临床症状几乎完全消退,未出现新病变。据我们所知,这是首例通过同时应用维生素D3类似物(卡泊三醇)和皮质类固醇(倍他米松),以凝胶形式组合在一种商业产品中治疗寻常型银屑病等角质形成细胞增殖性疾病,并在短时间内完全治愈的成功报告。由于两种成分的协同作用,即卡泊三醇一方面使角质形成细胞增殖正常化,另一方面皮质类固醇减轻炎症,这种有前景的新组合似乎更有效。鉴于存在恶变风险,防晒和定期临床观察始终必不可少。